Hyperfine (HYPR) Net Cash Flow Growth (5y) (2026)
Hyperfine (HYPR) Net Cash Flow Growth (5y) (2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 181.14 Bn | 173.84 Bn | 6.27 Bn |
| 2 | Stryker | 128.35 Bn | 125.47 Bn | 3.81 Bn |
| 3 | Medtronic | 107.95 Bn | 98.73 Bn | 6.41 Bn |
| 4 | Boston Scientific | 68.16 Bn | 66.71 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 47.67 Bn | 44.00 Bn | 1.29 Bn |
| 6 | GE HealthCare Technologies | 28.45 Bn | 26.17 Bn | 1.98 Bn |
| 7 | Dexcom | 28.45 Bn | 27.33 Bn | 750.30 Mn |
| 8 | Smith & Nephew | 26.83 Bn | 26.25 Bn | - |
| 9 | Koninklijke Philips | 25.36 Bn | 22.23 Bn | 2.07 Bn |
| 10 | Hyperfine | 98.67 Mn | 57.39 Mn | 1.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.97% |